Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.44 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | AHCY | P23526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293448 | 1.00 | FGFR1 (0.56) | FGFR1SLC22A6CYP3A4ENPP1ADORA2A | |
| SCHEMBL6054011 | 0.89 | FGFR1 (0.53) | FGFR1SLC22A6CYP3A4ENPP1ADORA2A | |
| SCHEMBL5662571 | 0.89 | FGFR1 (0.53) | FGFR1SLC22A6CYP3A4ENPP1ADORA2A | |
| SCHEMBL6053615 | 0.87 | FGFR1 (0.52) | FGFR1SLC22A6CYP3A4ENPP1ADORA2A | |
| SCHEMBL6053630 | 0.87 | FGFR1 (0.52) | FGFR1SLC22A6CYP3A4ENPP1ADORA2A | |
| SCHEMBL3294539 | 0.86 | CDK1 (0.46) | FGFR1SLC22A6CYP3A4ENPP1AHCY | |
| SCHEMBL13328630 | 0.86 | CYP3A4 (0.48) | FGFR1SLC22A6CYP3A4ADORA2AADORA1 | |
| SCHEMBL4279921 | 0.84 | CYP3A4 (0.47) | FGFR1SLC22A6CYP3A4ENPP1ADORA2A | |
| SCHEMBL4279920 | 0.84 | ADORA2A (0.48) | FGFR1SLC22A6CYP3A4ENPP1ADORA2A | |
| SCHEMBL2904496 | 0.82 | FGFR1 (0.61) | FGFR1SLC22A6CYP3A4ENPP1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546164-A4 | (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF | LG LIFE SCIENCES LTD (KR) | 2006-06-07 | — | — | EP | disclosed |
| US-20060111324-A1 | (+)-Ttrans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl)methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof | LG LIFE SCIENCES (KR) | 2006-05-25 | — | — | US | disclosed |
| EP-1546164-A1 | (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF | LG Life Sciences Ltd. (KR) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029064-A1 | (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF | LG LIFE SCIENCES LTD. (KR) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111324-A1 | (+)-Ttrans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl)methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof | TTR, HAVCR2, PNP | FGFR1 2540/4885SLC22A6 1606/4885CYP3A4 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.